XBiotech (XBIT) Receivables - Other (2022 - 2026)

XBiotech has reported Receivables - Other for 5 years, with the latest figure at $277000.0 in Q2 2026.

• On a quarterly basis, Receivables - Other changed N/A year-over-year to $277000.0 in Q2 2026; TTM through Jun 2026 was $277000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $360000.0, down 48.57% from the prior year.
• Receivables - Other was $277000.0 for Q2 2026 at XBiotech, down from $360000.0 in the prior quarter.
• The five-year high for Receivables - Other was $3.2 million in Q2 2023, with the low at $277000.0 in Q2 2026.
• Average Receivables - Other over 5 years is $1.3 million, with a median of $860000.0 recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other decreased 18.6% in 2024, then tumbled 48.57% in 2025.
• Over 5 years, Receivables - Other stood at $1.2 million in 2022, then retreated by 29.28% to $860000.0 in 2023, then fell by 18.6% to $700000.0 in 2024, then sank by 48.57% to $360000.0 in 2025, then decreased by 23.06% to $277000.0 in 2026.
• The last three Receivables - Other figures came in at $277000.0 (Q2 2026), $360000.0 (Q4 2025), and $700000.0 (Q4 2024), per Business Quant data.